Many of the cases of colon cancer present early symptoms similar to those of IBS, or irritable bowel syndrome, since both ...

The FDA has updated the label indication for linaclotide capsules for the treatment of irritable bowel syndrome with ...

The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older. Previously, ...

FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.

The FDA has approved linaclotide (Linzess) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation, according to a Nov. 5 news release. Linzess is the first ...

B. Longum is known as a “good bacteria” that helps break down food and absorb nutrients, which can help ease digestive ...

The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...

Rifaximin is as effective as the low-FODMAP diet in managing irritable bowel syndrome and offers quicker symptom relief and ...

Initially approved in 2012, linaclotide is already indicated for treating chronic idiopathic constipation and IBS-C in adults ...

Living with irritable bowel syndrome can often feel like a delicate balance between food and fear. One day, a simple meal ...

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. The updated outlook comes as Ibsrela continues to ...

In a groundbreaking study, British scientists have found that the Mediterranean diet could be the most effective way to ...